The high degree of structural similarity between dermaseptin-PD-1, dermaseptin-PD-2 and dermaseptin B2 (Figure 2), especially that between the latter two peptides, may indicate similar anticancer effect of the two novel peptides, particularly on prostate cancer cells. Here, PAF1 is linked to prostate cancer.